The Medical University of Innsbruck is a university in Innsbruck, Austria. It used to be one of the four historical faculties of the Leopold-Franzens-Universität Innsbruck and became an independent university in 2004.

During the past decade, Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 5 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 2 clinical trials were completed. i.e. 28.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie" #1 sponsor was "Arbeitsgemeinschaft medikamentoese Tumortherapie" with 10 trials, followed by "Hoffmann-La Roche" with 8 trials sponsored, "Institut de Recherches Internationales Servier" with 1 trials sponsored, "Taiho Oncology, Inc." with 1 trials sponsored and "University of Ulm" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie" #1 collaborator was "Celgene Corporation" with 3 trials as a collaborator, "Roche Pharma AG" with 3 trials as a collaborator, "Assign Data Management and Biostatistics GmbH" with 2 trials as a collaborator, "Sanofi" with 2 trials as a collaborator and "ADIR, a Servier Group company" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie" are "Chronic Myelomonocytic Leukemia" (2 trials), "Leukemia, Lymphocytic, Chronic, B-Cell" (2 trials), "Lymphocytic Leukemia, Chronic" (2 trials), "Acute Myeloid Leukemia" (1 trials) and "Acute Myeloid Leukemia (AML)" (1 trials). Many other conditions were trialed in "Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie" in a lesser frequency.

Most popular intervention types in "Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie" are "Drug" (20 trials), "Biological" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (3 trials), "Bevacizumab" (3 trials), "Lenalidomide" (3 trials), "Obinutuzumab" (3 trials) and "Rituximab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie" are 21 trials for "All" genders.

Currently, there are NaN active trials in "Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie". undefined are not yet recruiting, 2 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie, 5 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".